Zyprexa (Olanzapine): Advanced Neurochemical Stabilization for Schizophrenia and Bipolar Disorder
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.05 | $91.37 (0%) | 🛒 Add to cart |
| 60 | $2.23 | $182.74 $133.54 (27%) | 🛒 Add to cart |
| 90 | $1.96 | $274.11 $176.71 (36%) | 🛒 Add to cart |
| 120 | $1.82 | $365.48 $218.88 (40%) | 🛒 Add to cart |
| 180 | $1.69
Best per pill | $548.21 $304.23 (45%) | 🛒 Add to cart |
| Product dosage: 2.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.46 | $41.17 (0%) | 🛒 Add to cart |
| 120 | $0.40 | $54.89 $48.19 (12%) | 🛒 Add to cart |
| 180 | $0.35 | $82.33 $63.26 (23%) | 🛒 Add to cart |
| 270 | $0.32 | $123.50 $85.34 (31%) | 🛒 Add to cart |
| 360 | $0.30
Best per pill | $164.66 $108.44 (34%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $3.58 | $107.43 (0%) | 🛒 Add to cart |
| 60 | $2.63 | $214.87 $157.64 (27%) | 🛒 Add to cart |
| 90 | $2.32 | $322.30 $208.84 (35%) | 🛒 Add to cart |
| 120 | $2.16 | $429.74 $259.05 (40%) | 🛒 Add to cart |
| 180 | $2.00
Best per pill | $644.60 $359.45 (44%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.89 | $53.21 (0%) | 🛒 Add to cart |
| 90 | $0.80 | $79.82 $72.29 (9%) | 🛒 Add to cart |
| 120 | $0.76 | $106.43 $91.37 (14%) | 🛒 Add to cart |
| 180 | $0.73 | $159.64 $130.53 (18%) | 🛒 Add to cart |
| 270 | $0.70 | $239.47 $188.76 (21%) | 🛒 Add to cart |
| 360 | $0.69
Best per pill | $319.29 $247.00 (23%) | 🛒 Add to cart |
| Product dosage: 7.5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.08 | $62.25 $62.25 (0%) | 🛒 Add to cart |
| 60 | $1.64 | $124.50 $98.40 (21%) | 🛒 Add to cart |
| 90 | $1.49 | $186.75 $134.54 (28%) | 🛒 Add to cart |
| 120 | $1.42 | $249.01 $170.69 (31%) | 🛒 Add to cart |
| 180 | $1.34 | $373.51 $241.98 (35%) | 🛒 Add to cart |
| 270 | $1.30
Best per pill | $560.26 $350.41 (37%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Zyprexa (olanzapine) is an atypical antipsychotic medication engineered for the comprehensive management of schizophrenia and bipolar I disorder. It functions through a sophisticated mechanism, primarily antagonizing dopamine D2 and serotonin 5-HT2A receptors, to restore neurochemical balance in the central nervous system. This action provides robust control over acute psychotic and manic episodes while supporting long-term mood stabilization. Its clinical profile is characterized by high efficacy in reducing positive and negative symptoms, making it a cornerstone in modern psychiatric pharmacotherapy for eligible patients under strict medical supervision.
Features
- Active pharmaceutical ingredient: Olanzapine.
- Available in standard oral tablets, orally disintegrating tablets (Zyprexa Zydis), and a short-acting intramuscular injection formulation.
- Demonstrated high affinity for serotonin 5-HT2A, dopamine D1-4, muscarinic, histamine H1, and alpha1-adrenergic receptors.
- Extensive clinical trial data supporting its use in acute and maintenance treatment phases.
- Multiple dosage strengths available for precise titration (e.g., 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg).
Benefits
- Achieves rapid control of acute agitation, hallucinations, delusions, and disorganized thinking in schizophrenia.
- Effectively reduces the severity of acute manic or mixed episodes associated with bipolar I disorder.
- Provides prophylactic efficacy for the maintenance treatment of bipolar I disorder, delaying the time to recurrence of mood episodes.
- Helps to ameliorate the negative symptoms of schizophrenia, such as social withdrawal and apathy, in some patients.
- Offers a well-established pharmacokinetic profile with once-daily dosing to support treatment adherence.
- The availability of an intramuscular formulation offers a critical option for the rapid management of acute agitation in a controlled setting.
Common use
Zyprexa (olanzapine) is indicated for the treatment of schizophrenia. It is used to manage the manifestations of the psychotic disorder, including positive symptoms (e.g., hallucinations, delusions) and negative symptoms. It is also indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder and as maintenance monotherapy for bipolar I disorder. In some clinical contexts, it may be used off-label as an adjunctive treatment for treatment-resistant depression or for the control of agitation in certain medical conditions, though this is not its primary FDA-approved purpose.
Dosage and direction
Dosage must be individualized based on the patient’s clinical status, therapeutic response, and tolerability. The recommended starting dose for schizophrenia and bipolar I disorder is 5-10 mg once daily, without regard to meals. The dosage may be adjusted at intervals of not less than 24 hours, increasing in 5 mg increments up to a target range of 10-15 mg daily. Efficacy in schizophrenia has been demonstrated in a dose range of 10-20 mg/day; however, daily doses above 20 mg are not routinely recommended. For maintenance treatment in bipolar I disorder, the dose employed during the acute phase is typically continued. For the intramuscular formulation, the recommended dose for acute agitation is 10 mg. A lower dose of 2.5-5 mg may be considered for patients who are elderly, debilitated, or have a predisposition to hypotensive reactions. A second injection of 10 mg may be administered 2 hours after the first, or a third injection 4 hours after the second, with a maximum of three injections per 24 hours.
Precautions
Zyprexa carries a Boxed Warning for increased mortality in elderly patients with dementia-related psychosis; it is not approved for this use. Use with extreme caution in patients at risk of aspiration pneumonia due to its potential to cause dysphagia. Olanzapine use has been associated with weight gain, dyslipidemia, and hyperglycemia, which may increase the risk of developing metabolic syndrome and diabetes mellitus; baseline and periodic monitoring of weight, blood glucose, and lipid profiles is mandatory. Orthostatic hypotension, which may be associated with dizziness, tachycardia, and syncope, can occur, especially during initial dose titration. It should be used cautiously in patients with known cardiovascular disease, cerebrovascular disease, or conditions that would predispose them to hypotension. Due to its potential to cause somnolence, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain the medication does not affect them adversely. Neurologic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD) are rare but serious risks associated with all antipsychotic drugs.
Contraindications
Zyprexa is contraindicated in patients with a known hypersensitivity to olanzapine or any components of the formulation. Hypersensitivity reactions, including rash, urticaria, and anaphylaxis, have been reported.
Possible side effect
A wide range of side effects has been observed. Very common (≥1/10) side effects include weight gain, somnolence, sedation, dizziness, and elevated prolactin levels. Common (≥1/100 to <1/10) side effects include orthostatic hypotension, akathisia, parkinsonism, dry mouth, increased appetite, asthenia (weakness), peripheral edema, and mild, transient anticholinergic effects. Uncommon but serious side effects include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (TD), seizures, venous thromboembolism, and significant transaminase elevations. The metabolic effects—including significant weight gain, hyperglycemia (which may be extreme and associated with ketoacidosis or hyperosmolar coma), and dyslipidemia—require ongoing clinical attention.
Drug interaction
The action of olanzapine may be potentiated by other centrally acting drugs and alcohol, increasing the risk of sedation and orthostatic hypotension. Concurrent use with antihypertensive agents may potentiate hypotensive effects. Fluvoxamine (a CYP1A2 inhibitor) and other potent CYP1A2 inhibitors can significantly increase olanzapine concentrations; dose reduction of olanzapine may be necessary. Carbamazepine (a CYP1A2 inducer), omeprazole, and rifampin may increase the clearance of olanzapine, decreasing its efficacy. Olanzapine may antagonize the effects of levodopa and dopamine agonists. Due to its potential to induce orthostatic hypotension, caution is advised when co-administering with other drugs known to cause this effect.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not take a double dose to make up for a missed one.
Overdose
In pre-marketing experience, acute overdose of olanzapine alone was rarely fatal. Signs and symptoms of overdose are typically an exaggeration of its known pharmacological effects and may include severe drowsiness, sedation, impaired consciousness, confusion, agitation, tachycardia, hypotension, respiratory depression, and anticholinergic effects such as dry mouth and reduced gastrointestinal motility. Medical attention is critical. There is no specific antidote. Establish and maintain a clear airway and ensure adequate oxygenation and ventilation. Cardiovascular monitoring is essential. Gastric lavage and administration of activated charcoal may be considered. Supportive measures, including management of hypotension and circulatory shock, should be instituted. Close medical supervision and supportive therapy should continue until the patient recovers.
Storage
Store Zyprexa tablets and Zydis tablets at room temperature, 15°-30°C (59°-86°F). Protect from light and moisture. Keep the blister strips sealed in the original carton until use. Keep this and all medications out of the reach of children and pets.
Disclaimer
This information is for educational purposes only and is not a substitute for the professional judgment of a qualified healthcare provider in diagnosing and treating patients. The information provided does not cover all possible uses, directions, precautions, drug interactions, or adverse effects. The prescriber or pharmacist should be consulted for complete and current information specific to a patient’s circumstances before initiating or modifying any treatment regimen. The reader should not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare provider.
Reviews
“Zyprexa has been a pivotal agent in our inpatient formulary for managing acute psychosis. Its efficacy in rapidly de-escalating agitation is notable, though we maintain a rigorous protocol for monitoring metabolic parameters from initiation onward.” – Staff Psychiatrist, Academic Medical Center.
“In my outpatient practice for bipolar maintenance, olanzapine has provided remarkable stability for several of my most challenging cases. The trade-off, invariably, is metabolic monitoring; it demands a proactive and collaborative approach with the patient’s primary care physician.” – Board-Certified Psychiatrist.
“While the therapeutic effect for positive symptoms is robust, the side effect burden, particularly weight gain and sedation, often leads to discussions about adherence and long-term quality of life, necessitating a careful risk-benefit analysis for each individual.” – Clinical Pharmacist Specialist, Psychiatry.